Gyeongnam Venture Investment

Gyeongnam Venture Investment is a venture capital firm established in 2019 and located in Gyeongsangnam-Do, South Korea. The company focuses on investments in a variety of sectors, including the internet, communication, Internet of Things (IoT), electricity, electronics, semiconductors, materials, automobiles, healthcare, biotechnology, and cultural content, which encompasses movies, performances, and musicals. Gyeongnam Venture Investment seeks opportunities in industries with significant growth potential, positioning itself as a key player in supporting innovative businesses in South Korea.

Kuk-hyeong Cho

CEO

15 past transactions

ROBOS

Series A in 2024
Robos is a robotics company that specializes in developing and implementing robotic systems for various industries. It combines self-developed biomaterial machine vision technology with robotics to create innovative solutions for manufacturing, food processing, and medical sectors. The company offers a range of services, including robot product hardware and software development, robot-applied system design, and custom design, as well as web and mobile system development. By doing so, Robos helps businesses enhance their productivity and efficiency through the integration of robotics technology.

KRISTIN

Series A in 2023
KRISTIN is a supplier of flat, sneakers, and boots.

Reset Company

Series A in 2023
Reset Company focuses on creating sustainable energy solutions and resource circulation systems. The company has developed an autonomous cleaning robot designed specifically for solar panels. This robot operates similarly to a windshield wiper, automatically moving across the surface of solar panels to remove contaminants and snow. By ensuring that solar panels remain clean, the robot helps maximize power generation efficiency and prevents revenue loss for solar power plants. Its design allows for installation on various types of terrain and structures, making it a versatile solution for maintaining the cleanliness and performance of solar energy systems.

Santa

Series A in 2023
Santa is pushing content creation to new limits. Didicast, an easy to use video editing software developed by Santa, is made for content creators that are determined to produce polished videos for anything from education to entertainment. By leveling the learning curve and throwing out the expenses required in traditional content creation, Santa is helping creators from around the world change the world.

ROBOS

Seed Round in 2023
Robos is a robotics company that specializes in developing and implementing robotic systems for various industries. It combines self-developed biomaterial machine vision technology with robotics to create innovative solutions for manufacturing, food processing, and medical sectors. The company offers a range of services, including robot product hardware and software development, robot-applied system design, and custom design, as well as web and mobile system development. By doing so, Robos helps businesses enhance their productivity and efficiency through the integration of robotics technology.

BiomATZ

Seed Round in 2023
BiomATZ is a biotechnology company focused on developing microbiome therapeutics through its proprietary platform. This innovative platform isolates and analyzes the complex interactions within gut microbiota to create cooperative microbial consortia. By leveraging a bank of intestinal microorganism strains, BiomATZ facilitates the identification of optimal functional strain combinations, which can enhance the efficacy of live biotherapeutic products. The company is dedicated to advancing personalized medicine and improving gut health solutions, with potential applications in pharmaceuticals, nutraceuticals, and functional foods. Through its research and development efforts, BiomATZ aims to contribute significantly to the field of microbiome science and its therapeutic applications.

Biome ATS

Seed Round in 2023
BioM ATS intends to provide the fundamental infrastructure required to progress the complex strain design platform and foster technical collaboration with microbiome firms through proof-of-concept (POC) of the complex strain design technology. It is a strategy to begin the platform business in earnest by the end of the year, with an emphasis on platform advancement and collaboration with industry, academia, research institutes, and the military.

Twinwiz

Seed Round in 2023
Twinwiz is a global materials company specializing in the manufacturing of liquid-type antibacterial and antiviral additives. The company operates a research institute focused on developing functional additives that provide antibacterial and antiviral properties without altering the appearance or physical characteristics of the products they enhance. By enabling the incorporation of these additives in small quantities into various resins, Twinwiz ensures that its clients receive colorless and transparent solutions capable of generating high metal ions. This innovative approach allows for effective antimicrobial protection while maintaining the integrity of the base materials.

UCI Therapeutics

Seed Round in 2022
UCI Therapeutics is a biopharmaceutical company focused on addressing the limitations of current drug therapies. The company specializes in the development of multi-target fusion CAR-NKJ cell therapies, which utilize a cell-based fusion approach. This innovative strategy aims to enhance the effectiveness of immune cell therapies specifically for solid tumors, thereby improving treatment outcomes in cancer patients. Through its research and development efforts, UCI Therapeutics seeks to create more effective therapeutic options in the field of oncology.

Eflow

Venture Round in 2022
Eflow is a hydraulic equipment manufacturing company focused on innovative mobility solutions. It specializes in the development and production of drive propulsion modules that integrate advanced technologies, including axial magnetic flux motors and various power sources such as lithium batteries and hydrogen fuel cells. Eflow aims to provide sustainable and efficient transportation options, exemplified by its hydrogen-powered bicycle, which offers an eco-friendly alternative to traditional vehicles. The company's commitment to smart mobility and filter technology positions it as a leader in the pursuit of cleaner and more efficient transportation solutions.

KRISTIN

Seed Round in 2022
KRISTIN is a supplier of flat, sneakers, and boots.

CTNS

Seed Round in 2021
CTNS is a manufacturer specializing in the development and production of secondary battery packs tailored for the battery industry. The company focuses on creating customized rechargeable battery solutions designed for various applications, including small and medium-sized e-mobility, camping and leisure activities, service robots, and logistics robots. By providing next-generation secondary batteries with high energy density and stability, CTNS aims to meet the evolving needs of its clients in an increasingly electrified market.

Mr. Dad

Seed Round in 2021
Mr. Dad is an e-commerce marketplace that specializes in selling a diverse range of food products. The company offers a variety of items, including meat, eggs, dairy products, fruits, and essential cooking ingredients. By providing customers with access to fresh food items, Mr. Dad caters to their dietary needs and preferences, facilitating convenient online shopping for everyday consumption.

Mezoo

Series A in 2021
Mezoo is a medical device manufacturing company focused on developing innovative biomedical sensor technology aimed at enhancing human health through accurate diagnoses. The company specializes in creating a small, patch-type electrocardiogram that adheres to the chest of the test subject. This device enables real-time monitoring of cardiac activity, allowing physicians to effectively manage and prevent heart disease in patients. Through its advanced technology, Mezoo contributes to improving health outcomes and advancing the field of medical diagnostics.

AffyXell Therapeutics

Series A in 2021
AffyXell Therapeutics, founded in January 2020 as a joint venture between Avacta and Daewoong, specializes in the development of innovative mesenchymal stem cell (MSC) therapies. The company focuses on creating next-generation cell and gene therapies aimed at treating inflammatory and autoimmune diseases, as well as preventing organ transplant rejection. By harnessing the potential of MSCs, which are recognized for their therapeutic capabilities, AffyXell aims to provide effective treatment options for various health conditions, thereby enhancing the quality of care delivered by healthcare professionals.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.